Shandong Xinhua Pharmaceutical (00719.HK) announced that the National Medical Products Administration recently approved the transfer of the marketing authorization holder for the lactulose oral solution (100ml:66.7g) "Drug Supplementary Application Approval Notice".
Lactulose oral solution is mainly used for chronic or habitual constipation: regulating the physiological rhythm of the colon; used for hepatic encephalopathy: treating and preventing hepatic coma or pre-coma state. According to the data, in 2023, the sales of lactulose oral solution in public medical institutions in China amounted to approximately RMB 1.769 billion.